Friday, May 9, 2025

Latest

Cineplex: Canaccord Lowers Target To $17 From $19

On February 11th, Cineplex Inc (TSX: CGX) reported its fourth quarter financial results. The company saw its revenues grow to $300 million, up almost 20% quarter over quarter but below the $443 million it saw during the December 2019 quarter. Cineplex’s gross profits came in at $145.8 million, up quarter over quarter but below the $226 million during the December 2019 quarter.

The company saw a negative operating profit compared to the positive $37.26 million in the December 2019 quarter. While net income came in at negative $21.78 million, up 35% quarter over quarter but below the positive number it reported during the December 2019 quarter. Theatre attendance grew to 20.1 million while box office and concession revenues per person for the quarter were $12.29 and $7.49 respectively.

Seven analysts cover Cineplex with the average 12-month price target sitting at C$17.79, or a 32% upside to the current stock price. Out of the 7 analysts, 1 has a strong buy rating, 4 analysts have buy ratings and 2 analysts have hold rating. The street high sits at C$20, which represents a 50% upside from the current stock price. The lowest 12-month price target sits at C$15.

Canaccord Genuity lowered their 12-month price target on Cineplex to C$17 from C$19 and reiterated their speculative buy rating on the name. They say that even though the company reported worse than expected numbers, the company is seeing “resilient underlying returns.”

For the results, Canaccord expected Cineplex to report revenues of $338.8 million. Of the $300.0 million in revenues reported, box office revenues came in $125.9 million or 69% of the pre-pandemic levels. This is below Canaccord’s 80% estimate, though management noted that the month of October was at 80% of the pre-pandemic level.

Canaccord gives a few key takeaways from the financial results and earnings call, where they say that P1AG saw good resiliency with revenues at 80% of pre-pandemic levels. Additionally, the company saw media revenues grow to $32.5 million, only slightly below their $37.2 million estimate, and that the company generated an average monthly cash flow of $439,000. Net debt came in at $483.1 million, slightly higher than the $480.5 million last quarter. Most notably, the bank covenant of 3.75x debt/adjusted EBITDA has been reinstated and has been extended until the second quarter of 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Cresco Labs: Canaccord Cuts Price Target On Muted Growth, Pricing Challenges

On August 17, Cresco Labs (CSE: CL) reported its second quarter financial results. The company...

Friday, August 19, 2022, 02:12:00 PM

Zoom: Analysts Anticipate $906 Million In Q1 Revenues

Zoom Video Communications (NASDAQ: ZM) will be reporting their first quarter financial results June 1st...

Tuesday, June 1, 2021, 11:21:00 AM

Verano: Analysts Expect Q3 Revenues Of $219.7 Million

Verano Holdings (CSE: VRNO) announced that they will be reporting their third quarter financials before...

Monday, November 15, 2021, 10:10:00 AM

Ayr Strategies: Canaccord Reiterates Rating Following Arizona Transaction

This week, Canaccord Genuity came out with a note reiterating their C$25 price target and...

Friday, November 6, 2020, 12:20:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM